33 results on '"Szymonifka, Jackie"'
Search Results
2. Validation of the Hip Disability and Osteoarthritis Outcome Score and Knee Injury and Osteoarthritis Outcome Score Pain and Function Subscales for Use in Total Hip Replacement and Total Knee Replacement Clinical Trials
3. Utility of Computed Tomography to Predict Ventricular Arrhythmias in Patients With Nonischemic Cardiomyopathy Receiving Cardiac Resynchronization Therapy
4. Cardiorenal status using amino-terminal pro–brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study
5. Diagnosing Prosthetic Joint Infections in Patients With Inflammatory Arthritis: A Systematic Literature Review
6. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays
7. Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway
8. A four-tier classification system of pulmonary artery metrics on computed tomography for the diagnosis and prognosis of pulmonary hypertension
9. Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy—The BIOCRT Study
10. Characterization and Prediction of Adverse Events From Intensive Chronic Heart Failure Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored Chronic Heart Failure Therapy (PROTECT) Study
11. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control
12. Factors Associated with Malpractice Claim Payout: An Analysis of Closed Emergency Department Claims
13. A prospective trial of real-time magnetic resonance–guided catheter placement in interstitial gynecologic brachytherapy
14. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
15. Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma
16. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103
17. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
18. Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
19. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
20. Computed Tomography−Guided Assessment of Response to Cardiac Resynchronization Therapy
21. General Assembly, Diagnosis, Laboratory Test: Proceedings of International Consensus on Orthopedic Infections
22. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival
23. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003
24. SERIAL COMPUTED TOMOGRAPHY PULMONARY ARTERIAL MEASUREMENTS PREDICT SURVIVAL IN PULMONARY HYPERTENSION PATIENTS
25. USEFULNESS OF ATHEROSCLEROTIC PLAQUE DIFFUSENESS AND VOLUME BY CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY FOR PREDICTING CORONARY LESION-SPECIFIC ISCHEMIA BY FRACTIONAL FLOW RESERVE
26. DUAL-SOURCE COMPUTED TOMOGRAPHY TO IMPROVE PREDICTION OF RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY (DIRECT): A PROSPECTIVE DOUBLE-BLIND RANDOMIZED STUDY
27. SOLUBLE ST2 IS AFFECTED BY PULMONARY HYPERTENSION SEVERITY IN PATIENTS UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY
28. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
29. Characterization and Prediction of Adverse Events from Intensive Chronic Heart Failure Management with and without NT-proBNP Guidance: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study
30. Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,
31. Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol
32. Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide
33. Only Concomitant Presence of Cytogenetic Abnormalities in Randomly Sampled Bone Marrow and in MRI-Defined Focal Lesions Imparts Poor Prognosis and Is Associated with Gene Expression Profiling (GEP)-Based High-Risk Myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.